Back to News
Market Impact: 0.2
Cullinan Therapeutics Outlines Q4 Milestones For T Cell Engager Pipeline
Source: Nasdaq
Healthcare & BiotechCorporate Guidance & Outlook
Cullinan Therapeutics outlined planned fourth-quarter 2026 milestones across its immunology and oncology pipeline. Expected clinical updates will cover velinotamig, CLN-978 and CLN-049, creating potential catalysts for CGEM, although no clinical efficacy or financial data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
CGEM0.35
More News
- Banks, investors grow wary of AI debt, spooked by market selloff
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- Trade Desk faces earnings test as revenue forecast tumbles
- CorMedix stock gains as Heron deal adds four products
- Credicorp earnings on deck as digital push meets climate risk